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invOBJECTIVES The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial
enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with
aspirin þ clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity
(HPR) after TAVI.
BACKGROUND Current recommendations support short-term use of aspirin þ clopidogrel for patients with severe AS
undergoing TAVR despite the lack of compelling evidence.
METHODS This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6
different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12
reaction units (PRU) $208. Patients with HPR before TAVR were randomized to either aspirin þ ticagrelor or aspirin þ
clopidogrel for 3 months. Patients without HPR continued with aspirin þ clopidogrel (registry cohort). The primary
endpoint was non-HPR status (PRU <208) in $70% of patients treated with ticagrelor at 90 days post-TAVR.
RESULTS A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273  09) and were randomized to
aspirin þ ticagrelor (n ¼ 24, PRU 277  08) or continued with aspirin þ clopidogrel (n ¼ 24, PRU 269  49). The
remaining 20 patients (29%) without HPR (PRU 133  12) were included in the registry. Overall, platelet reactivity across
all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with
clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients
with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at
baseline developed HPR status during the first month after TAVR.
CONCLUSIONS HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR.
Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet
Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) (J Am Coll Cardiol Intv 2019;12:22–32)
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23AB BR E V I A T I O N S
AND ACRONYM S
ARU = aspirin reaction unit(s)
AS = aortic stenosis
DAPT = dual antiplatelet
therapy
HPR = high platelet reactivity
PRU = P2Y12 reaction unit(s)
TAVR = transcatheter aortic
valve replacementT ranscatheter aortic valve replacement(TAVR) for degenerative aortic stenosis(AS), the most common valvular heart dis-
ease in the elderly (1), has become an established
treatment for patients of high or intermediate surgi-
cal risk because it offers superior quality of life and
similar mortality rates at 2 years follow-up, with less
invasiveness than surgical aortic valve replacement
(2,3). Application of this technique in younger pa-
tients and those of lower surgical risk is currently be-
ing explored.SEE PAGE 33In patients undergoing TAVR, thrombotic and
hemorrhagic complications remain a concern, and are
associated with increased mortality and morbidity
(4–6). Although the immediate procedural risk relates
to vascular access and valvular debris embolization,
an significant percentage of thrombotic complications
takes place in the first days after the procedure and
during follow-up, remaining raised for up to 6 months
(4–7). These are non–procedural-related events and
implies the presence of a prothrombotic environment
in these patients. Therefore, antiplatelet treatment
plays an important role in trying to maintain the
balance between the suppression of thrombotic
complications without increasing the risk of bleeding.
Presently, antithrombotic therapy in patients with
AS undergoing TAVR is not standardized. Various
combinations of antithrombotic regimens (single-an-
tiplatelet, dual antiplatelet therapy [DAPT], or oral
anticoagulants) have been used, but evidence-based
guidance is limited. Current guidelines (8,9) for the
management of patients with valvular heart disease
recommend DAPT combining low-dose aspirin and a
thienopyridine (clopidogrel) for up to 6 months after
TAVR. However, the evidence for this recommenda-
tion is weak and has no support from dedicated ran-
domized clinical trials. Therefore, there is
heterogeneity in antithrombotic treatment regimens
following TAVR in real-world practice (10,11).
Studies have demonstrated a broad variability in
individual response profiles to clopidogrel therapy
resulting in adverse clinical outcomes, particularly
among those who persist with high platelet reactivity
(HPR) (12–14). However, most of these studies have
been conducted in patients undergoing coronaryentry, database maintenance, statistical analysis, and drafting and submissio
by the investigators. AstraZeneca played no role in the design of the study, da
or in the decision to submit for publication. The authors have reported that t
this paper to disclose.
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files of platelet reactivity in AS patients un-
dergoing TAVR treated with clopidogrel.
Moreover, the impact of newer generation
P2Y12 inhibitor such as ticagrelor character-
ized by more potent and less heterogeneous
antiplatelet effects has never been prospec-
tively tested in AS patients undergoing TAVR.
Therefore, we aimed to analyze profiles of
platelet reactivity among patients with AS
undergoing TAVR treated with clopidogrel, on
a background of aspirin therapy, and to assess the ef-
fects of ticagrelor among patients presenting with HPR.
METHODS
STUDY DESIGN AND PATIENT POPULATION. The
REAC-TAVI trial (Assessment of platelet REACti-
vity after Transcatheter Aortic Valve Implantation,
NCT02224066) was a prospective, open-label, inves-
tigator-initiated, randomized, multicenter, parallel-
group, phase IV pharmacodynamic clinical trial,
designed to investigate the incidence of HPR with
aspirin and clopidogrel in patients with severe
symptomatic AS undergoing TAVR and to test the
hypothesis that ticagrelor is superior to clopidogrel in
suppression of HPR after TAVR. An outline of the
study design is provided in the Online Appendix.
In brief, patients with severely symptomatic
degenerative AS undergoing TAVR by transfemoral
access were included at 7 centers in Spain (see the
Online Appendix for the participating centers). Pa-
tients were excluded if they had any of the following:
stroke during the 14 days before TAVR, bleeding
diathesis, need for long-term oral anticoagulation
treatment, contraindications to DAPT for 3 months,
platelet count <50,000/ml, severe hepatic dysfunc-
tion, use of potent CYP3A inhibitors or inducers. All
patients were on a background of aspirin (100 mg/
day) in adjunct to clopidogrel. Patients need to be on
clopidogrel maintenance dosing (75 mg/day) for $4
days before TAVR. Clopidogrel-naive patients were
pretreated with a 300-mg loading dose.
Patients with HPR at baseline were randomized in a
1:1 ratio using computerized random-number
generation in an interactive web response system by
an independent investigator to either continuen of the final manuscript was exclusively performed
ta analysis, data interpretation, writing of the report,
hey have no relationships relevant to the contents of
17, 2018, accepted October 2, 2018.
FIGURE 1 Study Flow Chart
ASA ¼ acetylsalicylic acid; PRU¼ P2Y12 reactivity units; TAVR ¼ transcatheter aortic valve
replacement.
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24clopidogrel (75 mg/day) or switch to ticagrelor (90
mg/twice daily). Patients randomized to the ticagrelor
group received at least 3 maintenance doses before
undergoing TAVR. Patients without HPR were
included in a registry cohort and maintained on clo-
pidogrel therapy.
The TAVR procedure was performed according to
the standards of each participating center. Patients
received intravenous heparin (100 U/kg), with addi-
tional doses if the activated clotting time was <250 s.
Compliance to antiplatelet therapy was assessed by
the 4-item Morisky Green Levine Medication Adher-
ence Scale (15) at 30 and 90 days after TAVR and by
accountability of the study drugs in both treatment
arms. Onsite monitoring and source data verification
were conducted by an independent contract research
organization in 100% of patients and in all study
procedures, with a final follow-up visit at 4 months
after TAVR. Adverse events were adjudicated by an
independent clinical events committee, according theValve Academic Research Consortium-2 classification
(16). The study flow chart is showed in Figure 1. The
study complied with the Declaration of Helsinki, the
International Conference on Harmonization/Good
Clinical Practice guidelines, and applicable regulatory
requirements. Informed consent was obtained and
documented for all patients before conducting any
study-related procedures.
PLATELET REACTIVITY ASSESSMENT. Platelet func-
tion was assessed using the VerifyNow point-of-care
assay (Accriva Diagnostics, San Diego, California).
Measurements were conducted in all patients at
baseline (before TAVR) and at 6 different time points
following TAVR: 6 h 30 min, 24 2 h, 5 1 day, 30 3
days, and 90  5 days. HPR was defined as a P2Y12 re-
action unit (PRU) value $208, in line with consensus
recommendations (17,18). Response to aspirin was also
assessed; an aspirin reaction unit (ARU) value $550
defined patients as nonresponders to aspirin. All pa-
tients were included in the per protocol safety anal-
ysis, whereas the pharmacodynamic analysis at 30
days consisted of 61 patients: 1 patient in the registry
was excluded from the analyses due to missing
platelet reactivity data results; 2 patients (1 in the
ticagrelor group and 1 in the clopidogrel group) were
excluded due to development of new-onset atrial
fibrillation during hospitalization and were switched
to oral anticoagulation; and 4 patients died during
hospitalization (2 in the clopidogrel group and 2 in the
registry group). At 90 days, 2 patients died in the clo-
pidogrel group. The final pharmacodynamic popula-
tion at 90 days, therefore, comprised 59 patients
(ticagrelor n ¼ 23; clopidogrel n ¼ 19; registry n ¼ 17).
STUDY ENDPOINTS. The primary endpoint was to
obtain non-HPR status (PRU <208) in $70% of pa-
tients treated with ticagrelor, or a net difference
of $40% in the number of patients with PRU <208
between treatment groups at 90  5 days of anti-
platelet treatment following TAVR. A key secondary
efficacy endpoint was the net difference in the inci-
dence of HPR 6 h post-TAVR of $30% between groups.
The secondary safety endpoints are constituted by
the incidence of cerebrovascular accident or hemor-
rhagic complications (according to Valve Academic
Research Consortium-2 criteria) at 4-month follow-up
following TAVR. Exploratory endpoints included the
analysis of patients with HPR after 24 h, 5 days, and
30 days of antiplatelet treatment, and pre-specified
subanalyses by sex, age, comorbidities (diabetes
mellitus, renal failure), type of bioprosthetic valve
implanted, and HPR to both antiplatelet agents.
SAMPLE-SIZE CALCULATION AND STATISTICAL METHODS.
Statistical inference was based on comparison of the
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25incidence of the primary endpoint between treatment
groups. To achieve 80% power to detect differences
in the contrast of the null hypothesis H₀:p1 ¼ p2 using
a chi-square test for 2 independent samples with a ¼
0.05, a treatment arm allocation ratio of 1:1, under the
assumption that the proportion of patients achieving
adequate antiplatelet therapy at 3 months post-TAVR
(PRU <208) in the aspirin þ clopidogrel group is 28%
and the proportion expected in the aspirin þ tica-
grelor group is 70%, it was necessary to enroll 21 pa-
tients in each treatment group. Given an expected
dropout rate of 10%, 24 patients in each treatment
group (total n ¼ 48) would be required.
Conformity to the normal distribution was evalu-
ated for continuous variables with the Shapiro-Wilk
test. Categorical variables are expressed as fre-
quencies and percentages. For baseline characteris-
tics, continuous variables are expressed as mean 
SD; PRU and ARU as mean  SE. Chi-square tests or
Fisher exact tests were used, where appropriate, to
compare categorical variables between 2 groups. Pri-
mary analysis of the difference between ticagrelor
and clopidogrel in PRU at 90 days was analyzed using
a 2-sample Student’s t-test. Two-sample Student’s
t-tests were also used to evaluate other intergroup
comparisons and to evaluate the impact of the 2
different treatments on platelet reactivity across time
points.
RESULTS
PATIENT POPULATION. Between November 2015 and
May 2017, of 73 patients screened, 68 patients met
study entry criteria (3 patients had difficulties
completing the follow-up visit, 1 patient was switched
to non-transfemoral TAVR, and 1 patient was
excluded due to physician decision). Most patients
were on long-term use ($4 days) of clopidogrel (84%),
whereas the remaining patients received a loading
dose. A total of 48 patients (71%) had HPR at baseline
(PRU 273  09) and were randomized to continue
treatment with clopidogrel (n ¼ 24, PRU 269  49) or
to switch to ticagrelor (n ¼ 24, PRU 277  08). The
remaining 20 patients (29%) without HPR (PRU 133 
12) were included in the registry (Figure 1). Baseline
ARU was 456  15 in the randomized group and 451 
18 in the registry group; an ARU >550 was present in 9
patients (13%) (ARU 587  10). Of these, 5 patients
were in the registry group. Thus, 4 patients had HPR
to both aspirin and clopidogrel, and were distributed
equally in both randomized groups.
Baseline characteristics of the study population are
displayed in Table 1. Compared with the randomized
group, patients in the registry cohort had a lowerprevalence of chronic kidney disease and higher he-
moglobin levels. Baseline characteristics were similar
between randomized groups, except for lower body
mass index and mean aortic valve area, and higher
STS-PROM score in the clopidogrel group compared
with the ticagrelor group. The majority of patients
had pre-existing cardiovascular risk factors, nearly
one-half of the population were women, had dia-
betes, or had prior percutaneous coronary interven-
tion, and more than one-quarter of patients had a
history of myocardial infarction or chronic kidney
disease.
All patients were treated by transfemoral access,
with a predominance of a conscious sedation strategy
in the randomized group and general anesthesia in
the registry. Procedural success was achieved in
>90%, and a balloon-expandable valve was used in
48% of cases (Table 2).
PHARMACODYNAMIC RESULTS. Overall, platelet reac-
tivity across all the study time points after TAVR was
lower in patients receiving ticagrelor compared with
those receiving clopidogrel, including the registry
group (p < 0.001). The primary endpoint of patients
with PRU <208 was achieved in 100% of patients with
ticagrelor compared with 21% with clopidogrel (PRU
240  15; p < 0.001), with a net difference of re-
sponders between groups of 79% (p < 0.001) and an
overall mean difference of 170 PRU in the ticagrelor
group compared to clopidogrel group at the end of the
treatment. Analysis of PRU levels at the different
time-points also showed a significant reduction of
platelet reactivity at 6 h, 24 h, 5 days, and 30 days
with ticagrelor, compared with clopidogrel (p <
0.001) (Figure 2). The percentage of responders to
ticagrelor was significantly higher throughout the
entire treatment period compared with responders to
clopidogrel (Figure 3). Interestingly, important varia-
tions in PRU levels throughout the treatment period
was observed in the registry group, with an increase
of 53  26 PRU (Figure 2) and a decrease of 33% re-
sponders during the first month after TAVR (Figure 3).
A total of 23 patients had at least 1 PRU value #70
during the treatment period: 1 in the clopidogrel
group, 18 in the ticagrelor group, and 4 in the registry
group. Mean ARU values were maintained in ranges
of adequate response during the treatment period in
the 3 groups, but significant variations in the degree
of response to aspirin between groups were noticed at
5 and 30 days post-TAVR (Figure 4). The proportion of
patients responding to aspirin did not vary signifi-
cantly during the treatment phase.
SAFETY RESULTS. There was a total of 55 adverse
events adjudicated by the clinical events committee
TABLE 1 Baseline Characteristics of the Study Population
Normal Platelet
Reactivity
Registry (n ¼ 20)
*p Value
Registry vs.
Randomized
†p Value
Registry vs.
Clopidogrel þ Aspirin
‡p Value
Registry vs.
Ticagrelor þ Aspirin
High On-Treatment Platelet Reactivity
§p Value
Clopidogrel þ Aspirin
(n ¼ 24)
Ticagrelor þ Aspirin
(n ¼ 24)
Demographic characteristics
Age, yrs 75.8  19.6 0.31 0.25 0.31 81.2  5.5 80.3  8.6 0.67
Women 9 (45.0) 0.58 0.95 0.54 11 (45.8) 13 (54.2) 0.56
BMI, kg/m2 26.3  4.5 0.10 0.48 0.004 27.3  4.77 30.6  4.6 0.02
Cardiovascular risk factors
Current smokers 5 (25.0) 0.56 0.92 0.43 6 (25.0) 3 (12.5) 0.46
Hypertension 16 (80.0) 0.96 0.67 0.64 19 (79.2) 22 (91.7) 0.41
Diabetes mellitus 8 (40.0) 0.12 0.10 0.43 16 (66.7) 13 (54.2) 0.37
Insulin-treated 2 (10.0) 0.19 0.08 1.00 8 (33.3) 3 (12.5) 0.08
Dyslipidemia 11 (55.0) 0.29 0.55 0.13 16 (66.7) 19 (79.2) 0.33
History of cardiovascular
disease and procedures
PVD 0 (0.0) 0.18 0.24 1.00 3 (12.5) 1 (4.2) 0.29
CKD 2 (10.0) 0.03 0.14 0.07 8 (33.3) 9 (37.5) 0.76
COPD 2 (10.0) 0.71 0.36 0.56 5 (20.8) 4 (16.7) 0.71
Chronic liver disease 1 (5.0) 0.84 1.00 1.00 2 (8.3) 1 (4.2) 1.00
Stroke 1 (5.0) 0.63 0.61 1.00 3 (12.5) 1 (4.2) 0.29
TIA 1 (5.0) 0.89 1.00 0.45 2 (8.3) 0 (0) 0.48
Myocardial infarction 5 (25.0) 0.56 0.47 0.72 4 (16.7) 5 (20.8) 0.71
PCI 10 (50.0) 0.52 0.47 0.54 10 (41.7) 10 (41.7) 1.00
CABG 0 (0.0) 0.16 0.24 0.24 3 (12.5) 3 (12.5) 1.00
Clinical data
Dyspnea 16 (80.0) 0.96 1.00 0.64 19 (79.2) 22 (91.7) 0.41
Angina 4 (20.0) 0.53 1.00 0.50 5 (20.8) 8 (33.3) 0.33
Syncope 3 (15.0) 0.41 0.64 0.64 2 (8.3) 2 (8.3) 1.00
NYHA II to III 14 (70.0) 0.07 0.29 0.29 22 (95.7) 23 (95.8) 1.00
Echocardiographic data
Maximum aortic gradient, mm Hg 80.6  24.5 0.42 0.94 0.33 81.1  17.5 70.7  23.0 0.10
Mean aortic gradient, mm Hg 51.8  17.8 0.06 0.45 0.06 47.9  11.6 41.1  13.3 0.08
Mean aortic valve area, cm2 0.61  0.17 0.29 0.93 0.04 0.62  0.20 0.73  0.13 0.05
Aortic regurgitation $moderate 3 (15.0) 0.11 0.29 0.28 1 (5.3) 1 (4.8) 1.00
LVEF 60.5  12.7 0.52 0.30 0.96 55.9  12.9 60.8  15.3 0.28
Systolic PAP 52.3  15.6 0.08 0.29 0.04 41.7  13.2 36.2  8.1 0.34
Blood analysis
Hemoglobin, mg/dl 13.4  1.6 0.01 0.009 0.02 12.0  1.8 12.2  1.8 0.62
Platelets, 109/l 203.1  71 0.95 0.78 0.67 197.3  62 211.7  60 0.42
NT-proBNP 1,901  1,496 0.41 0.27 0.83 4,226  5,178 2,104  2,103 0.33
Risk scores
Logistic EuroScore 8.9  6.11 0.21 0.11 0.71 13.37  10.37 9.52  5.31 0.12
STS-PROM, % 6.36  7.61 0.73 0.67 0.23 7.22  5.18 4.08  2.53 0.014
HAS-BLED 2.75  1.30 0.63 0.87 0.34 2.69  0.90 2.40  0.81 0.25
CHA2DS2-VASC 4.00  1.41 0.15 0.11 0.39 4.70  1.36 4.38  1.41 0.43
Values are mean  SD or n (%). *p values of comparison between registry group and randomized group. †p values of comparison between registry group and clopidogrel þ aspirin group. ‡p values of
comparison between registry group and ticagrelor þ aspirin group. §p values of comparison between both randomized groups.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼
N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association functional class; PAP ¼ pulmonary arterial pressure; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular
disease; STS ¼ Society of Thoracic Surgeons; TIA ¼ transient ischemic attack.
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26in the overall population during the entire study.
There were no statistically significant differences in
the incidence of major bleeding or cardiovascular
death among the study groups at 4 months follow-up,as well as other adjudicated adverse events according
VARC-2 definitions (Table 3). Only 1 patient had an in-
hospital major bleeding related to vascular access
while on a PRU value of 70 at 6 h after TAVR.
TABLE 2 Procedural Characteristics and In-Hospital Outcome
Normal Platelet
Reactivity
Registry (n ¼ 20)
*p Value
Registry vs.
Randomized
†p Value
Registry vs.
Clopidogrel þ Aspirin
‡p Value
Registry vs.
Ticagrelor þ Aspirin
High On-Treatment Platelet Reactivity
§p Value
Clopidogrel þ Aspirin
(n ¼ 24)
Ticagrelor þ Aspirin
(n ¼ 24)
Procedural data
Local anesthesia only 3 (15.0) 0.003 0.10 <0.001 3 (12.5) 1 (4.2) 0.07
Conscious sedation 5 (25.0) 14 (58.3) 21 (87.5)
General anesthesia 12 (60.0) 7 (29.2) 2 (8.3)
Transfemoral access 20 (100.0) 1.00 1.00 1.00 24 (100) 24 (100.0) 1.00
Balloon pre-dilation 4 (20.0) 1.00 1.00 1.00 5 (20.8) 5 (20.8) 1.00
Balloon size, mm 23.3  1.5 0.01 0.17 0.008 20.7  2.3 19.8  1.1 0.48
Valve type, size, and post-dilation
Balloon-expandable valve 6 (30.0) 9 (37.5) 14 (58.3)
Self-expandable valve 9 (45.0) 11 (45.8) 9 (37.5)
Other type of valve 5 (25.0) 0.37 0.86 0.11 4 (16.7) 1 (4.2) 0.21
#23-mm valve 0 (0.0) 0.10 0.10 0.11 7 (29.2) 7 (29.2) 0.83
25- to 29-mm valve 18 (90.0) 15 (62.5) 16 (66.7)
>29-mm valve 2 (10.0) 2 (8.3) 1 (4.1)
Balloon post-dilation 5 (25.0) 0.70 1.00 0.64 6 (25.0) 3 (12.5) 0.46
Balloon size, mm 24.3  0.96 0.38 0.38 0.49 22.7  2.3 23.3  2.3 0.76
Vascular closure
2 ProGlides 13 (65.0) 0.66 0.63 0.71 19 (79.2) 16 (66.7) 0.58
Prostar 5 (25.0) 3 (12.5) 4 (16.7)
Surgical closure 2 (10.0) 2 (8.3) 4 (16.7)
Procedural outcome
Procedural success 18 (90.0) 1.00 NA 1.00 23 (96) 23 (87.5) 1.00
Final maximum gradient, mm Hg 17.9  15.8 0.37 0.26 0.29 7.0  4.6 11.4  8.1 0.17
Final mean gradient, mm Hg 8.7  8.1 0.75 0.35 0.78 4.8  3.7 9.8  5.5 0.11
Final AR $moderate 2 (10.0) 0.13 0.08 0.35 1 (4.1) 3 (12.5) 0.35
Total dose of UFH, UI 5,090  2,634 0.02 0.06 0.03 6,904  2,462 7,000  2,161 0.89
Need of valve recapture and reposition 2 (10.0) 0.59 0.60 0.60 2 (8.3) 2 (8.3) 1.00
Need for a second valve 0 (0.0) NA NA NA 0 (0) 0 (0.0) NA
Conversion to open-heart surgery 0 (0.0) NA NA NA 0 (0) 0 (0.0) NA
Need of permanent pacemaker implantation 3 (15.0) 0.71 1.00 1.00 5 (20.8) 5 (20.8) 1.00
Hospital stay, days 7.9  3.6 0.86 0.88 0.85 7.7  4.0 7.6  5.6 0.93
Values are n (%), or mean  SD. *p values of comparison between the registry group and the randomized group. †p values of comparison between the registry group and the clopidogrel þ aspirin group.
‡p values of comparison between the registry group and the ticagrelor þ aspirin group. §p values of comparison between both randomized groups. Other type of valve includes Lotus valve and Direct Flow
valve.
AR ¼ aortic regurgitation; UFH ¼ unfractionated heparin.
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27DISCUSSION
To date, there are limited studies evaluating profiles
of platelet reactivity in patients with severe AS un-
dergoing TAVR (19–21). The present study is the first
to our knowledge to prospectively evaluate profiles of
platelet reactivity of patients with AS undergoing
TAVR treated with aspirin plus clopidogrel therapy
and to evaluate the effects of ticagrelor among pa-
tients with HPR. The main results of our study are as
follows: 1) HPR to clopidogrel is present in more than
two-thirds of patients with AS undergoing TAVR; 2)
more than one-third of patients who were identified
to be responders to clopidogrel developed HPR status
during the first month after TAVR; and 3) ticagrelor ishighly effective for the suppression of HPR to clopi-
dogrel after TAVR with reduced rates of HPR
observed already a few hours after valve implantation
and with consistent effects throughout the treatment
period.
Previous studies have demonstrated that platelet
reactivity is abnormally increased in patients with
valvular heart disease, generating deposition of
platelets and formation of thrombi on the surface of
altered or diseased, natural heart valves (22). This
may act as a nidus for microthrombi formation
in vivo. Increased platelet activation and the throm-
bogenic environment in patients with severe AS un-
dergoing aortic bioprosthesis implantation might be
related to: 1) high transvalvular gradient leading to
FIGURE 3 Responders to P2Y12 Inhibitors
TAVR ¼ transcatheter aortic valve replacement.
FIGURE 2 Mean PRU Values During 3 Months of Treatment Following TAVR
HPR ¼ high platelet reactivity; other abbreviations as in Figure 1.
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FIGURE 4 Mean ARU Values During 3 Months of Treatment Following TAVR
ARU ¼ aspirin reactivity units; NS, nonsignificant; other abbreviations as in Figures 1 and 2.
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29increased shear stress and endothelial injury, thereby
promoting platelet adhesion and activation; 2) altered
aortic blood flow and activation of various pro-
thrombotic factors (23–26) (von Willebrand factor,
factor VIII); 3) exposure of subendothelial thrombus-
producing materials and release of activated throm-
botic factors, such as tissue factor and thrombin, from
degenerated native aortic valve leaflets (27) into the
circulation generating microthromboemboli (28); and
4) poor antiplatelet effects leading to accumulation of
fibrin in the stent valve and microthrombi formation
on the nonendothelialized surface of the bovine
pericardial tissue leaflets, due to microfissures
(potentially produced during crimping) prone to
platelet adhesion (Figure 5).
Also, abnormal functional characteristics of plate-
lets in patients with valvular heart disease have been
documented, compared with normal subjects,
consisting of morphological alterations and with
subendothelial components, such as collagen fibers,
exposed to the circulating blood with platelet aggre-
gates adhering to collagen fibers. Moreover, abnor-
mally increased thromboplastic activity and
decreased fibrinolytic capacity in histopathology
analysis of rheumatic mitral valves have been
described (29). These features may explain thehyperactive platelet response found in these patients
sustaining a thrombogenic environment.
Platelets are well known to play a major role
in coronary stent thrombosis and adequate anti-
platelet therapy protects against this phenomenon
(17,18,30–34). However, the role of platelets and thus
that of antiplatelet therapy in the development of
clinical (transient ischemic attack, stroke, valve
thrombosis) or subclinical (hypoattenuated leaflet
thickening and reduced leaflet motion) thrombotic
events after a percutaneous or surgical implant of an
aortic bioprosthesis (35–37) is less established. Theo-
retically, poor antiplatelet response (i.e., presence of
HPR) after bioprosthesis implantation could promote
fibrin deposition and platelet aggregation, favoring
the thickening of valvular leaflets and bioprosthetic
structures, a phenomenon that would end with the
formation of thrombotic material. Symptomatic
increased pressure gradients with thickened leaflet
tips, leaflet adhesion, and impairing proper opening
but with no evidence of thrombi have been described
after early discontinuation of DAPT, with complete
resolution after DAPT resume (38). Also, acute cere-
bral occlusion by a fresh thrombus consisting mainly
of accumulations of fibrin and platelets during TAVR,
have been reported (39). Ongoing clinical trials are
TABLE 3 Clinical Events at 4-Month Follow-Up
Normal Platelet
Reactivity
Registry (n ¼ 20)
*p Value
Registry vs.
Randomized
†p Value
Registry vs.
Clopidogrel þ Aspirin
‡p Value
Registry vs.
Ticagrelor þ Aspirin
High On-Treatment Platelet Reactivity
§p Value
Clopidogrel þ Aspirin
(n ¼ 24)
Ticagrelor þ Aspirin
(n ¼ 24)
Death 2 (10.0) 1.00 0.67 0.20 4 (16.7) 0 (0.0) 0.10
Stroke 1 (5.0) 0.50 1.00 0.45 1 (4.2) 0 (0.0) 1.00
Myocardial infarction 1 (5.0) 0.29 0.45 0.45 0 (0.0) 0 (0.0) NA
Major bleeding 1 (5.0) 0.15 0.54 0.61 7 (29.2) 3 (12.5) 0.28
MACE 3 (15.0) 0.68 0.71 0.08 5 (20.8) 0 (0.0) 0.05
NACE 4 (20.0) 0.43 0.07 0.68 11 (45.8) 3 (12.5) 0.01
All bleeding events 1 (5.0) 0.09 0.05 0.35 7 (29.2) 4 (16.7) 0.49
Acute renal failure 0 (0.0) 1.00 NA 1.00 0 (0.0) 1 (4.2) 1.00
Vascular complication 0 (0.0) 0.55 0.49 1.00 2 (8.3) 1 (4.2) 1.00
Vascular closure device failure 0 (0.0) 0.55 1.00 0.49 1 (4.2) 2 (8.3) 1.00
Arrhythmias and conduction disturbances 2 (10.0) 0.19 0.15 0.25 7 (29.2) 6 (25.0) 1.00
Values are n (%). *p values of comparison between the registry group and the randomized group. †p values of comparison between the registry group and the clopidogrel þ aspirin group. ‡p values of
comparison between the registry group and the ticagrelorþ aspirin group. §p values of comparison between both randomized groups. All events are according Valve Academic Research Consortium-2 criteria.
MACE includes death, stroke, and myocardial infarction. NACE includes death, stroke, myocardial infarction, and major bleeding.
MACE ¼ major adverse cardiovascular event(s); NACE ¼ net adverse clinical event(s).
FIGURE 5 Potential Factors Leading to Increased Platelet
Activation and Prothrombotic Environment in Patients
With AS Undergoing TAVR
AS ¼ aortic stenosis; TAVR ¼ transcatheter aortic valve
replacement.
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30evaluating oral anticoagulation and DAPT in TAVR
patients without atrial fibrillation and will help to
define the role of platelets and thrombin on throm-
botic events after TAVR (Global Study Comparing a
rivAroxaban-based Antithrombotic Strategy to an
antipLatelet-based Strategy After Transcatheter
aortIc vaLve rEplacement to Optimize Clinical Out-
comes [GALILEO], NCT02556203; Dual Antiplatelet
Therapy Versus Oral Anticoagulation for a Short Time
to Prevent Cerebral Embolism After TAVI [AUREA],
NCT01642134).
The TAVR population is continuously increasing
and poses unique challenges on implementing the
optimal antithrombotic regimen. Overall, our results
confirm the superior potency of ticagrelor over clopi-
dogrel to achieve prompt and potent platelet inhibi-
tory effects in a new challenging scenario, comparable
to what has been described in prior investigations
conducted in other clinical settings (40,41). Notably,
by the 6-h time point after TAVR, <10% of ticagrelor-
treated patients still had HPR. The suppression of
HPR with ticagrelor was reached in 100% at 5 days
post-TAVR, remaining unchanged during follow-up in
all patients. Furthermore, the fact that over 30% of
patients initially responding to clopidogrel became
nonresponders during the first month after valve im-
plantation, highlights the significant increase in
platelet reactivity induced by the bioprosthetic valve
implantation procedures and its components at an
early stage (use of large-bore catheters and stiff
guidewire in the left ventricle, pre-/post-dilation with
disruption of native aortic valve leaflets, and calcifi-
cations of the aortic valve annulus and aortic arch), aswell as the poor efficacy of clopidogrel to maintain
adequate platelet inhibition during the following 3
months after TAVR.
Therefore, ticagrelor represent an attractive alter-
native to clopidogrel, not only to treat HPR, but also
to prevent this from occurring in patients who may pre-
sent with optimal response to clopidogrel before TAVR.
Platelet reactivity seems to be a dynamic phenom-
enon, giving relevance to the effect of the timing of
measurement on the level of reactivity. Also, interin-
dividual variability in the platelet inhibitory response
PERSPECTIVES
WHAT IS KNOWN? Lack of compelling evidence exists on the
efficacy of aspirin þ clopidogrel as antithrombotic treatment in
patients with severe AS undergoing TAVR.
WHAT IS NEW? HPR to clopidogrel is present in a considerable
number of patients with AS undergoing TAVR and more than one
third of patients initially responders to clopidogrel become
nonresponder during the treatment period. Ticagrelor achieves a
better and faster effect providing sustained suppression of HPR
to these patients.
WHAT IS NEXT? Larger clinical trials are needed to assess the
clinical implications of these findings.
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31to clopidogrel has been demonstrated in patients un-
dergoing elective coronary stenting. Gurbel et al. (42),
found that the maximum inhibitory response to a 300-
mg loading dose of clopidogrel occurs within 24 h. In
GRAVITAS (Gauging Responsiveness With A Ver-
ifyNow Assay-Impact On Thrombosis And Safety) trial
(43), HPR measured 12 to 24 h after percutaneous cor-
onary intervention resolved at the 30-day follow-up in
38% of the patients randomly assigned to standard-
dose clopidogrel. In our study, 79% of patients were
on long-term (>30 days) use of clopidogrel, and the
remaining 29% clopidogrel-naive patients received a
300-mg loading dose, with evaluation of platelet
reactivity 24 h after the loading dose. This heteroge-
neity to timing of baseline platelet function assess-
ment with relationship to timing of clopidogrel intake
may explain why 21% of patients initially identified to
be nonresponders became responders after TAVR.
Furthermore, the Hawthorne effect could also have a
role in this change. Hence, the clinical, procedural, and
genetic predictors of the early resolution of HPR after
TAVR deserve further evaluation.
STUDY LIMITATIONS. The HPR cutoff point used in
our study was the cutoff recommended for the eval-
uation of thrombotic events in patients with coronary
artery disease. But, the HPR cutoff for assessing
thrombotic events in the TAVR population is still
unclear. Given the pharmacodynamic design of the
study, it was underpowered for clinical endpoints war-
ranted by adequately powered studies for this purpose.
CONCLUSIONS
Our data suggest that patients undergoing TAVR for
severe AS and treated with clopidogrel have highrates of residual platelet reactivity during the peri-
procedural period, with a significant increase in
platelet reactivity during the first month after TAVR
and that may last for up to 3 months thereafter,
casting doubts of its efficacy in this setting. Ticagrelor
achieves a better and faster effect, providing sus-
tained benefit to these patients over the course of the
treatment period without safety concerns. Larger
studies are urgently needed to define its clinical
benefit in this setting.
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